Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Navi Medical Secures A$6.8 Million to Commercialise Neonav® in US Paediatric Care
3+ hour, 26+ min ago (716+ words) 30 July 2026 | Thursday | News Melbourne- and Boston-based medical device company Navi Medical Technologies has closed a $A6.8 million capital raise to commercialise its breakthrough paediatric vascular access technology in the United States. Neonav® ECG Tip Location System in a neonatal clinical setting....
HoneyNaps Expands Global CRO Services with AI-Powered Sleep Analytics Platform
1+ day, 3+ hour ago (543+ words) BioPharma APAC - HoneyNaps Expands Global CRO Services with AI-Powered Sleep Analytics Platform 29 July 2026 | Wednesday | News - Strengthens specialized AI-powered sleep data analysis services for global pharmaceutical, medical device, and healthcare companies - Targets the rapidly growing global sleep clinical research market with…...
Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours
1+ day, 3+ hour ago (508+ words) BioPharma APAC - Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours 29 July 2026 | Wednesday | News Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug…...
Waters Launches Next-Generation IVD Mass Spectrometer for High-Sensitivity Clinical Diagnostics
1+ day, 3+ hour ago (96+ words) 29 July 2026 | Wednesday | News Featuring the new StepWave™ XR Ion Guide, the Xevo TQ Absolute XR IVD System delivers improved robustness, enabling ion ratio consistency for up to six times longer compared with the Xevo TQ Absolute IVD System.4 This advancement…...
APAC Physicians Back Pulsed Field Ablation, But Referral Gaps Delay AFib Treatment
1+ day, 3+ hour ago (191+ words) 29 July 2026 | Wednesday | News Growing physician confidence in pulsed field ablation highlights the need to strengthen referral pathways, education and healthcare system readiness PFA in APAC, from Promise to Practice was commissioned by Boston Scientific to better understand physician perspectives on…...
Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics
1+ day, 3+ hour ago (593+ words) BioPharma APAC - Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics 29 July 2026 | Wednesday | News Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, announced…...
OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon
2+ day, 3+ hour ago (576+ words) BioPharma APAC - OrbusNeich Enrols First Patient in Pivotal Japanese Trial of Coronary Drug-Coated Balloon 28 July 2026 | Tuesday | News OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary…...
Stopped: The Six-Year Cost of Trials That Never Reached the Finish Line
2+ day, 14+ hour ago (1481+ words) 27 July 2026 | Monday | Analysis One infusion, no programme A gene therapy is a one-way door. The vector goes in once, it cannot be taken out, and with current adeno-associated virus technology the patient cannot be dosed again. Whatever a sponsor decides…...
AnHorn Medicines Advances First-in-Class AH-008 into Phase I Trial for Chemotherapy-Induced Neuropathy Prevention
2+ day, 22+ hour ago (278+ words) 27 July 2026 | Monday | News Addressing a Significant Unmet Medical Need Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and dose-limiting side effect of widely used cancer therapies, including taxanes, platinum-based agents, vinca alkaloids, and antibody-drug conjugates (ADCs). CIPN can cause numbness, tingling,…...
ArkBio Completes Dosing in Phase I Trial of Long-Acting Influenza Prevention Candidate AK0406
2+ day, 22+ hour ago (87+ words) 27 July 2026 | Monday | News Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that all cohorts of healthy volunteers have been dosed in an Australian Phase I trial with AK0406, a novel long-acting antiviral-Fc conjugate (AFC) drug for influenza prophylaxis. The clinical trial…...